LOT 1 - Human Health expertise with special attention on reproductive toxicity (including developmental neuro- and immunotoxicity), neurotoxicity and immunotoxicity

dressed (e.g. neurotoxicity, immunotoxicity, endocrine disruption) which require specific scientific and technical expertise in order to assess and identify these specific adverse properties. New and emerging methodologies (preferably without using animal testing) need to be assessed, developed or f

inetuned, allowing decision making within the framework of REACH and CLP. These new framework contracts will help the Agency to address these emerging scientific challenges, while at the same time provide support to ongoing or new regulator